Administration of an LXR agonist promotes atherosclerotic lesion remodelling in murine inflammatory arthritis.

Dragana DragoljevicMan Kit Sam LeeGerard PernesPooranee K MorganCynthia LouisWaled ShihataKevin HuynhArina A KochetkovaPatrick W BellNatalie A MellettPeter J MeikleGraeme I LancasterMichael J KraakmanPrabhakara R NagareddyBeatriz Y HanaokaIan P WicksAndrew J Murphy

Published in: Clinical & translational immunology (2023)

Taken together, we show that the LXR agonist T0901317 rescues impaired atherosclerotic lesion regression in murine arthritis because of enhanced cholesterol efflux transporter expression and reduced foam cell development in atherosclerotic lesions.

Keyphrases

rheumatoid arthritis
poor prognosis
single cell
cell therapy
mouse model
stem cells
binding protein
bone marrow